Feed aggregator

Less than 18 Months After Launch, Ohana Biosciences Closes Its Doors

Biospace news - Wed, 04/28/2021 - 02:00
Launched in January 2020 by Flagship Pioneering, Ohana was being dubbed a “first-in-category reproductive health company” focused on the industry’s first sperm biology platform.

Takeda Closes in on Potential Approval for NSCLC Drug, Mobocertinib

Biospace news - Wed, 04/28/2021 - 02:00
Takeda’s non-small cell lung cancer treatment Mobocertinib is leading closer to regulatory approval after the U.S. Food and Drug Administration granted priority review to the New Drug Application.

Two Research Leaders Share How CSL Behring Empowers Teams Across the Globe

Biospace news - Wed, 04/28/2021 - 02:00
As a devastating pandemic increased scientific collaboration globally, CSL was already ahead of the curve with teams spanning the continents, working together to advance lifesaving treatments and technologies.

Genentech's Tecentriq Survives FDA Accelerated Approval Vote in mTNBC

Biospace news - Wed, 04/28/2021 - 02:00
A U.S. FDA committee gave the nod to continue using Genentech’s checkpoint inhibitor Tecentriq in combination with chemotherapy to treat adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumors express PD-L1.

Cutting-Edge Biotechs Raise Investors' Hopes: Exscientia and Boundless Bio

Biospace news - Wed, 04/28/2021 - 02:00
Investors are still hungry for cutting-edge biotech companies that can make a difference in people’s lives with the hope of a big return on investment. Here’s a look at two recent big funding rounds.

Alpha 9, Engage Tech Raise Funds for Cancer Therapeutics, Improved Patient Journey

Biospace news - Wed, 04/28/2021 - 02:00
Alpha-9 Theranostics announced the closing of an $11 million Series A financing today, while Engage Technologies also announced it has raised money in a Series A round, funding that came in at a tune of $15 million.

Companies Betting Oral Vaccines, Therapies Will Boost Fight Against COVID-19

Biospace news - Wed, 04/28/2021 - 02:00
Researchers are continuing to develop next-generation therapeutics and oral vaccines that could overcome some vaccine hesitancy. Here are some of the top producers.

Novartis CEO Says Remote Work Hybrid Should Mean Access to New Talent Pools

Biospace news - Wed, 04/28/2021 - 02:00
Novartis AG Chief Executive Officer Vas Narasimhan believes that the hybrid of remote and on-site office work is the future.

Developing ‘Antennae’ for Drug Regulation and Policy: A Conversation with Geoffrey Levitt

Biospace news - Wed, 04/28/2021 - 02:00
Levitt has practiced law for over 20 years in the FDA regulatory space. Previously chief regulatory counsel for Pfizer Inc., Levitt has had extensive experience working with an interdisciplinary team of scientists, executives and lawyers to push a candidate to market.

Preparing a Pandemic Plan for Whatever Comes Our Way Next

Biospace news - Wed, 04/28/2021 - 02:00
According to Teo, the definition of the next pandemic depends a lot on one’s perspective.

Houston's Hope BioSciences Highlights Texas' Hotbed Status

Biospace news - Wed, 04/28/2021 - 02:00
Texas is quickly becoming a hotbed of biopharmaceutical activities, with Houston being one of the two top cities in the state that is leading the way.

FDA Issues CRL for Protalix and Chiesi's Fabry Disease Drug

Biospace news - Wed, 04/28/2021 - 02:00
The companies indicated they are studying the CRL to determine the best way to understand the problems and what course of action they might take.

7 Out-of-the-Box Strategies to Advance Your Career

Biospace news - Wed, 04/28/2021 - 02:00
Figuring out how to become a more qualified, competitive job candidate can seem overwhelming. Often it feels as if you only have a handful of options to build your resume in any meaningful way – like earning additional degrees or simply gaining several more years of experience in your role.

Hepatitis C drugs multiply effect of COVID-19 antiviral Remdesivir

World Pharma News - Tue, 04/27/2021 - 10:00
When combined with drugs currently used to treat hepatitis C, the antiviral remdesivir is 10 times more effective in treating cells infected with SARS-CoV-2, the virus that causes COVID-19.

Published this week in Cell Reports, this finding - from Gaetano Montelione, a professor of chemistry and chemical biology at Rensselaer Polytechnic Institute, and his collaborators at the Icahn School of Medicine at Mount Sinai and the University of Texas at Austin - raises the potential for repurposing available drugs as COVID-19 antivirals in cases where a vaccine isn't practical or effective.

As Drug Prices Climb, Politicians Squabble Over Best Approaches and Timing

Biospace news - Tue, 04/27/2021 - 02:00
Drug pricing tends to be a somewhat bipartisan issue, although how the Democrats and GOP approach the topic tends to be different.

New Emails Show Fear, Confusion Around Biogen Superspreader Conference

Biospace news - Tue, 04/27/2021 - 02:00
A multi-day conference hosted by Biogen during the early days of the COVID-19 pandemic has been determined to be a super-spreader event, with more than 300,000 infections linked to the conference.

With Anti-CD47 Cancer Drugs Trending, Arch Takes in $105 Million for its Antibody

Biospace news - Tue, 04/27/2021 - 02:00
The race is on in the CD47 field, and Brisbane-based player Arch Oncology just upped the bet with a $105 million Series C raise.

Ceding to Pressure, Biogen Will Offer Early Access to Tofersen in July

Biospace news - Tue, 04/27/2021 - 02:00
In phase one of the two-part program, access to tofersen will be granted on an individual basis to SOD1-ALS patients with an ALS Functional Rating Scale - Revised (ALSFRS-R) slope decline greater than or equal to 2 points per month.

Sun's Out to Play, But So Is Skin Cancer - Here's What Pharma is Doing About It

Biospace news - Tue, 04/27/2021 - 02:00
There are several experimental treatments undergoing study for types of melanoma. BioSpace rounds up some of the most recent clinical news in this space.

Trying Again, Enzyvant Resubmits BLA for Pediatric Congenital Athymia Drug

Biospace news - Tue, 04/27/2021 - 02:00
Enzyvant Sciences has resubmitted its Biologics Licensing Application to the U.S. FDA for its tissue-based regenerative pediatric congenital athymia therapy RVT-802.